Yangbing Zhao Selected Research

Muromonab-CD3 (Muromonab CD3)

1/2017	Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation.
9/2009	Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yangbing Zhao Research Topics

Disease

32	Neoplasms (Cancer) 01/2020 - 12/2003
5	Hematologic Neoplasms (Hematological Malignancy) 03/2016 - 12/2011
5	Melanoma (Melanoma, Malignant) 11/2010 - 01/2006
4	Testicular Neoplasms (Testicular Cancer) 01/2016 - 04/2005
4	Leukemia 05/2014 - 09/2009
3	Breast Neoplasms (Breast Cancer) 12/2017 - 07/2003
2	Carcinoma (Carcinomatosis) 02/2014 - 07/2003
2	Anaphylaxis (Anaphylactic Shock) 07/2013 - 07/2013
1	Prostatic Neoplasms (Prostate Cancer) 01/2018
1	Necrosis 12/2017
1	Communicable Diseases (Infectious Diseases) 05/2017
1	Lung Neoplasms (Lung Cancer) 01/2016
1	Neuroblastoma 11/2014
1	Fatty Liver 09/2014
1	Renal Cell Carcinoma (Grawitz Tumor) 03/2011
1	Alzheimer Disease (Alzheimer's Disease) 02/2011
1	Amyloid Plaque 02/2011
1	Mesothelioma 11/2010
1	Neoplasm Metastasis (Metastasis) 11/2010

Drug/Important Bio-Agent (IBA)

17	Chimeric Antigen ReceptorsIBA 12/2017 - 09/2009
11	AntigensIBA 01/2020 - 12/2003
8	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2020 - 07/2006
7	Messenger RNA (mRNA)IBA 12/2017 - 01/2006
7	RNA (Ribonucleic Acid)IBA 01/2017 - 04/2005
5	Neoplasm Antigens (Tumor Antigens)IBA 03/2016 - 07/2006
5	Peptides (Polypeptides)IBA 01/2016 - 04/2005
3	AntibodiesIBA 03/2016 - 07/2013
2	Biological ProductsIBA 01/2020 - 09/2014
2	CytokinesIBA 01/2018 - 10/2015
2	Pharmaceutical PreparationsIBA 12/2017 - 09/2014
2	Muromonab-CD3 (Muromonab CD3)FDA Link 01/2017 - 09/2009
2	Interleukin-2 (IL2)IBA 05/2014 - 11/2010
2	MesothelinIBA 02/2014 - 11/2010
2	Immunoglobulin E (IgE)IBA 07/2013 - 07/2013
1	VaccinesIBA 01/2018
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2018
1	Folic Acid (Vitamin M)FDA LinkGeneric 10/2015
1	Tumor Viral Antigens (Large T Antigen)IBA 09/2015
1	Hormones (Hormone)IBA 09/2014
1	Tamoxifen FDA LinkGeneric 09/2014
1	Anastrozole (Arimidex)FDA LinkGeneric 09/2014
1	EpitopesIBA 02/2014
1	Lysine (L-Lysine)FDA Link 03/2011
1	Alanine (L-Alanine)FDA Link 03/2011
1	Phenylalanine (L-Phenylalanine)FDA Link 03/2011
1	Serine (L-Serine)FDA Link 03/2011
1	Tyrosine (L-Tyrosine)FDA Link 03/2011
1	Presenilin-1IBA 02/2011
1	Amyloid (Amyloid Fibrils)IBA 02/2011
1	Complement System Proteins (Complement)IBA 11/2010
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2010
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 11/2010
1	Histocompatibility Antigens Class IIBA 04/2010
1	HLA Antigens (Human Leukocyte Antigens)IBA 04/2010
1	HMW-MAAIBA 04/2010
1	Trastuzumab (Herceptin)FDA Link 11/2009
1	Histone Deacetylase InhibitorsIBA 03/2009
1	Interferon-gamma (Interferon, gamma)IBA 03/2009
1	ElementsIBA 03/2009
1	Decitabine FDA Link 03/2009
1	Therapeutic UsesIBA 03/2009
1	DepsipeptidesIBA 03/2009
1	HLA-A Antigens (HLA-A)IBA 05/2008
1	Amino Acids FDA Link 05/2008
1	gp100 Melanoma AntigenIBA 11/2006
1	HLA-DPw4 antigenIBA 07/2006
1	Complementary DNA (cDNA)IBA 07/2006
1	Tumor Suppressor Protein p53IBA 01/2006
1	Proteins (Proteins, Gene)FDA Link 11/2005
1	Antisense OligonucleotidesIBA 12/2003
1	invariant chain (Ii-Key)IBA 12/2003
1	ginsenoside Rg3IBA 07/2003

Therapy/Procedure

10	Therapeutics 01/2018 - 03/2009
9	Immunotherapy 01/2020 - 03/2009
2	Injections 12/2017 - 11/2010
1	Cell- and Tissue-Based Therapy (Cell Therapy) 09/2015
1	Intravenous Administration 02/2014
1	Drug Therapy (Chemotherapy) 08/2013
1	Investigational Therapies (Experimental Therapy) 03/2009